COGNICURRENT

World Obesity Day on March 4 aims to raise awareness and promote the prevention and treatment of obesity, a condition that poses significant health risks.

Experts highlight that the treatment of obesity in Brazil is hampered by inadequate diagnosis, lack of professional preparation, and insufficient medications within the SUS.

The expiration of semaglutide's patent in 2026 is expected to ignite competition among major global markets including China, India, the USA, Canada, and Brazil, particularly in the lucrative obesity treatment sector.

A medical expert in Brazil discusses the significance of recognizing obesity and lipedema as distinct chronic conditions that require proper diagnosis and individualized treatment.

A Paraguayan lab announced a drug for obesity treatment which lacks regulatory approval, as it is still in clinical trials despite promotional events.

The article discusses the rising prevalence of non-alcoholic fatty liver disease and highlights the important roles of magnesium and potassium in its treatment.

Novo Nordisk announced a plan to reduce the price of its anti-obesity drug Wegovy by 50% in the U.S. starting in 2027 to improve affordability and competitiveness.

Novo Nordisk's stock plummeted 15% after its new drug CagriSema failed to meet key weight-loss targets in a clinical trial compared to Eli Lilly's tirzepatide.

A study discusses the uncommon condition of functional testosterone deficiency in aging men and highlights misconceptions about its treatment methods.

A UK doctor shares his personal experience with the weight loss drug Mounjaro, detailing both physical and psychological effects during and after treatment.

A conference on the impact of overweight on health and society is being held in the Estonian Riigikogu with experts discussing preventative, treatment, and policy-making strategies.

A new AI-discovered therapy for obesity, ISM0676, presents potential advantages over existing GLP-1 receptor agonists, signifying a major shift in obesity treatment.

Lilly, the American multinational, is investing 153 million euros in expanding its production plant in Alcobendas, Spain, to significantly increase its capacity for producing obesity treatment pills.

Brazil's health agency Anvisa warns against the use of weight loss pens for obesity and diabetes treatment without medical oversight due to rising cases of pancreatitis.

A new program in South Korea aims to provide free obesity treatment to patients with rare diseases and low-income individuals.

Research indicates that the benefits of the obesity medication tirzepatide fade away after patients discontinue their treatment, with significant weight regain observed in many cases.

Medicines like GLP-1 have revolutionized obesity treatment, significantly impacting attitudes towards weight loss in the U.S.

There has been a surge in illegal sales of unauthorized diet drugs impersonating Korean Lilly, particularly through social media, amidst growing interest in obesity treatments.

An international group of experts has published a consensus document aiming to standardize the diagnosis and treatment of lipedema, a chronic condition characterized by disproportionate fat accumulation, pain, and sensitivity, previously confused with obesity or lymphedema.

Semaglutide by Novo Nordisk is the first drug approved for obesity treatment that achieves weight loss comparable to bariatric surgery, while Eli Lilly's tirzepatide is expected to gain approval soon after showing efficacy and safety in clinical trials.

The Ministry of Health reported encouraging results from its childhood obesity program and the expansion of the program to cover kidney dysfunction with over 36,460 recipients for free obesity treatment.

Approximately 350 children are receiving treatment for obesity at the Children's Hospital in Reykjavik, with around 120 to 130 on weight control medications, and it is estimated that about 500 children in Iceland have fatty liver disease.

A health event discussing the treatment of obesity in adults is taking place at Veröld- house Vigdísar, featuring lectures including one by family doctor Erla Gerður Sveinsdóttir.

The article discusses GLP-3s, a new generation of weight-loss drugs that target multiple hormones to enhance obesity treatment.

The first oral weight loss pill, Wegovy, is now available by prescription for patients in the United States, marking a significant milestone in the fight against obesity.